739 related articles for article (PubMed ID: 18506010)
1. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
2. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
Pignone M; Earnshaw S; Pletcher MJ; Tice JA
Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
[TBL] [Abstract][Full Text] [Related]
3. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
4. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
[TBL] [Abstract][Full Text] [Related]
7. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
9. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
[TBL] [Abstract][Full Text] [Related]
10. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
Ess SM; Szucs TD
Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
[TBL] [Abstract][Full Text] [Related]
11. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
13. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
14. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
Greving JP; Visseren FL; de Wit GA; Algra A
BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
[TBL] [Abstract][Full Text] [Related]
15. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
Johannesson M
Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
Hur C; Simon LS; Gazelle GS
Cancer; 2004 Jul; 101(1):189-97. PubMed ID: 15222006
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of preventive treatment of intracranial aneurysms: new data and uncertainties.
Greving JP; Rinkel GJ; Buskens E; Algra A
Neurology; 2009 Jul; 73(4):258-65. PubMed ID: 19299311
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
[TBL] [Abstract][Full Text] [Related]
20. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]